343,467 results match your criteria Lymphoproliferative Disorders


CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

University of Virginia School of Medicine, Charlottesville, Virginia, USA.

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targeted cells allows for optimal induction of complement-dependent cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207266DOI Listing
February 2019

Folliculotropic mycosis fungoides in a pediatric patient mimicking black dot tinea capitis.

Pediatr Dermatol 2019 Feb 21. Epub 2019 Feb 21.

Section of Pediatric Dermatology, Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.

Immunosuppression following organ transplantation is a known risk factor for the development of lymphoproliferative disorders. Mycosis fungoides, a rare entity in pediatric patients, has seldom been reported as a post-transplant lymphoproliferative disorder. We report a case of folliculotropic mycosis fungoides in a pediatric patient following liver transplantation that was initially diagnosed as tinea capitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13768DOI Listing
February 2019

Novel mutations of STXBP2 and LYST associated with adult haemophagocytic lymphohistiocytosis with Epstein-Barr virus infection: a case report.

BMC Med Genet 2019 Feb 19;20(1):34. Epub 2019 Feb 19.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.

Background: Haemophagocytic lymphohistiocytosis is a life-threatening disease resulting from primary or secondary hyper-inflammatory disorders. The typical symptoms include persistent fever, splenomegaly, cytopenia and significant elevation of serum ferritin.

Case Presentation: We report a 30-year-old Chinese female patient who was diagnosed with chronic active Epstein-Barr virus infection more than 9 months prior and has since been presenting with cutaneous lymphoproliferative disorders mimicking hydroa vacciniforme and subsequent haemophagocytic lymphohistiocytosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12881-019-0765-3DOI Listing
February 2019

BRAF in the cross-hairs.

Expert Rev Hematol 2019 Feb 20. Epub 2019 Feb 20.

a Leukemia Service , Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center , New York , NY , 10065 , USA.

Introduction: Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications. Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583553DOI Listing
February 2019

PCR GeneScan and Heteroduplex Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes for Clonality Diagnostics in Suspect Lymphoproliferations.

Methods Mol Biol 2019 ;1956:77-103

Laboratory Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.

Assessment of the presence of clonal lymphoproliferations via polymerase chain reaction (PCR)-based analysis of rearranged immunoglobulin (IG) or T-cell receptor (TR) genes is a valuable method in the diagnosis of suspect lymphoproliferative disorders. Additionally, this methodology can be used for evaluating dissemination of lymphoma cells and for studying the clonal relationship between multiple (different locations) or consecutive (over time) lymphomas. Here we describe an integrated approach to assess clonality via analysis of Ig heavy chain (IGH), Ig kappa (IGK), TCR beta (TRB), and TCR gamma (TRG) gene rearrangements, based on the standardized multiplex PCRs as originally developed by the European BIOMED-2 consortium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_4DOI Listing
January 2019

Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma.

Clin Infect Dis 2019 Feb 19. Epub 2019 Feb 19.

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, and Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.

Biallelic mutations in the ITK gene cause a T-cell primary immunodeficiency with Epstein-Barr virus (EBV)-lymphoproliferative disorders. We describe a novel association of a homozygous ITK mutation with β-human papillomavirus (HPV)-positive epidermodysplasia verruciformis. Thus, loss of function in ITK can result in broad dysregulation of T-cell responses to oncogenic viruses, including β-HPV and EBV. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/cid/advance-article/doi/10.1093/cid
Publisher Site
http://dx.doi.org/10.1093/cid/ciy942DOI Listing
February 2019
3 Reads

Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

Pediatr Rheumatol Online J 2019 Feb 14;17(1). Epub 2019 Feb 14.

Division of Immunolgy, Boston Children's Hospital, Boston, MA, USA.

Background: Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were historically thought to be distinct entities, often managed in isolation. In fact, these conditions are closely related. A collaborative approach, which incorporates expertise from subspecialties that previously treated HLH/MAS independently, is needed. Read More

View Article

Download full-text PDF

Source
https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-
Publisher Site
http://dx.doi.org/10.1186/s12969-019-0309-6DOI Listing
February 2019
5 Reads

Head trauma complicated with primary cranial vault lymphoma: A case report.

Medicine (Baltimore) 2019 Feb;98(7):e14465

Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian.

Rationale: Primary cranial vault lymphoma (PCVL) is an extremely rare extranodal lymphoma in the skull. This case study investigates the clinical features, so as to improve the understanding of the diagnosis and therapy.

Patient Concerns: A 31-year-old male presented painful scalp mass at the site of 1-month-old head trauma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014465DOI Listing
February 2019
1 Read
5.723 Impact Factor

Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders.

Int J Immunopathol Pharmacol 2019 Jan-Dec;33:2058738419829387

3 Department of Pharmacology, Wuhan University, Wuhan, P.R. China.

There is a significant overlap between intestinal lymphoproliferative disorders (LPDs) and inflammatory conditions of the intestine, including inflammatory bowel disease (IBD), in clinical, endoscopic, or histologic appearance, leading to diagnostic challenges. We report two cases of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) that were initially considered to be ulcerative colitis (UC) and lymphocytic colitis, respectively. Both patients presented with diarrhea and abdominal pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2058738419829387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376542PMC
February 2019
1 Read

Biopsy needles for mediastinal lymph node sampling by endosonography: current knowledge and future perspectives.

J Thorac Dis 2018 Dec;10(12):6960-6968

Pulmonology Unit, Department of Thoracic Diseases, G B Morgagni L Pierantoni Hospital, Forli, Italy.

Due to the increasing role of endosonography [endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and esophageal ultrasound-guided fine needle aspiration (EUS-FNA)] in the diagnosis of several lung diseases, the knowledge of technical aspects is mandatory to optimize the success of the procedure. Among those technicalities related to the procedure, the choice of a needle over another one-either in terms of dimension and type-may have a role in the diagnostic process, especially in some diseases such as lymphoproliferative disorders. In this review, we analyze the current knowledge about the biopsy needle for endosonography, providing also some hints for the future. Read More

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/25652/19481
Publisher Site
http://dx.doi.org/10.21037/jtd.2018.11.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344676PMC
December 2018
2 Reads

Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.

Leuk Lymphoma 2019 Feb 10:1-4. Epub 2019 Feb 10.

a Department of Hematology and Oncology , Weill Cornell Medicine , New York , NY, USA.

Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common and potentially fatal complications after allogeneic transplantation with mismatched donors and T-cell depletion. Haplo-cord transplantation combines a mismatched UCB graft with third-party cells. Conditioning involves thymoglobulin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1543877DOI Listing
February 2019
1 Read

Methotrexate-associated lymphoproliferative disorder with multiple pulmonary nodules and bilateral cervical lymphadenopathy.

Auris Nasus Larynx 2019 Feb 7. Epub 2019 Feb 7.

Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

As has been well recognized, methotrexate (MTX) leads to a state of immunosuppression and can provide a basis for the development of lymphoproliferative disorders (LPDs). MTX-associated LPDs can affect nodal sites as well as extranodal sites, though the manifestation of an LPD in the form of multiple pulmonary nodules is rare. Here, we report two cases of MTX-associated LPD with multiple bilateral pulmonary nodules, which was a finding suggestive of lung cancer, and bilateral cervical lymphadenopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anl.2019.01.010DOI Listing
February 2019

[Essential mixed cryoglobulinemia type II: case report.]

Rev Fac Cien Med Univ Nac Cordoba 2018 11 13;75(4):292-298. Epub 2018 Nov 13.

.

The cryoglobulinemic syndrome is produced by precipitating immunoglobulins at low temperatures. Its production is associated with several causes, such as lymphoproliferative disorders, chronic infections and autoimmune disorders. However, the etiology is unknow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31053/1853.0605.v74.n3.17550DOI Listing
November 2018
2 Reads

Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand.

Pediatr Int 2019 Jan;61(1):49-57

Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries.

Methods: Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13739DOI Listing
January 2019
1 Read

Flow Cytometry Applications in the Diagnosis of T/NK-Cell Lymphoproliferative Disorders.

Cytometry B Clin Cytom 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.

This article provides an overview of the role of flow cytometry in the diagnosis, prognosis, and follow-up of T and NK-cell lymphoproliferative disorders. For each category, we will briefly discuss the immunophenotypic features of normal T and NK cells, and address technical issues in flow cytometry, the approach to diagnosis in various contexts, pitfalls in interpretation, and its use in follow-up and post-therapy management. In addition to reviewing the diagnostic, prognostic, and therapeutic utility of flow cytometric immunophenotyping in several of specific T and NK cell entities, we will also cover some of the new immunophenotypic markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21768DOI Listing
February 2019

First presentation of Sneddon-Wilkinson disease with unexpected immunoglobulin A gammopathy: A case report and review of the literature.

SAGE Open Med Case Rep 2019 30;7:2050313X19826432. Epub 2019 Jan 30.

University of Saskatchewan, Saskatoon, SK, Canada.

We present a case of Sneddon-Wilkinson disease in a 52-year-old female at her first presentation to dermatology. Outlined in the case are various investigations undertaken at this initial presentation, including rheumatologic and hematologic malignancy markers, which identified immunoglobulin A gammopathy. The systemic and topical therapies used to treat the patient's condition are described, as well as her response to these treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X19826432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354295PMC
January 2019
2 Reads

A Case of EBV-Associated Blastic Lymphoplasmacytic Proliferation in an Esophageal Ulcer with a Self-Limiting Course: Overlapping Lesion between EBV Mucocutaneous Ulcer and Polymorphic Lymphoplasmacytic Disorder.

Histopathology 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematopathology, Department of Pathology and Laboratory Medicine, University of Miami and, Sylvester Comprehensive Cancer Center, Miami, FL.

B cell lymphoproliferative disorders (LPD) of varied malignant potential occur in association with immunodeficiency and include among others, follicular hyperplasia, infectious mononucleosis-like hyperplasia, plasmacytic hyperplasia, polymorphic B-lymphoproliferative disorders and the recently described clinicopathologic entity named as EBV-positive mucocutaneous ulcer (EBV-MCU). EBV-MCU is a localized and usually self-limited EBV-associated LPD characterized by a circumscribed ulcer involving oropharyngeal mucosa, skin, or gastrointestinal tract reported most often in elderly patients with presumed age-associated immunodeficiency. Histologically, EBV-MCU is characterized by a polymorphous infiltrate, which frequently includes atypical large B cells with Hodgkin/Reed-Sternberg (HRS) like cells admixed with abundant reactive T cells usually forming a rim around the base of the lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13836DOI Listing
February 2019
1 Read

[Multiple myeloma associated with a secondary amyloidosis. Report of one case].

Rev Med Chil 2018 Nov;146(11):1351-1355

Servicio de Análisis Clínicos, Hospital Universitario Dr. Peset, Valencia, España.

Multiple Myeloma is a myeloproliferative disorder of plasma cells, which may be complicated with secondary amyloidosis. We report a 48 year old woman consulting to primary care for weight loss and malaise. An initial laboratory study revealed a hypogammaglobulinemia with a monoclonal component and lambda light chains. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872018001101351DOI Listing
November 2018
3 Reads

Lymphoprolipherative skin reactions induced by anti-TNFα: An open question.

J Dermatolog Treat 2019 Feb 6:1-14. Epub 2019 Feb 6.

a 1st Department of Dermatology "Andreas Syggros" Hospital, Medical School, National and Kapodistrian University of Athens , Athens , Greece.

Although anti-TNFα agents have revolutionized the treatment of many inflammatory diseases, various concerns have been reported regarding the risks of cancer development, as well as acceleration of the progression of subclinical, pre-existing malignancies. In this case series we investigated the provocative effect of anti-TNFα drugs in the development of cutaneous mycosis fungoides (MF)-like lymphoproliferative reactions. We describe 5 patients aged between 25-63 diagnosed with autoimmune disorders (psoriatic arthritis- one patient, Crohn's disease- one patient and ankylosing spondylitis- three patients) who received anti-TNFα agents before the development of a cutaneous lymphoproliferative reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1579889DOI Listing
February 2019
1 Read

Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression.

Clin Cancer Res 2019 Feb 4. Epub 2019 Feb 4.

Dermatology, University of Iowa

Purpose: Cutaneous T cell lymphomas (CTCL), encompassing a spectrum of T-cell lymphoproliferative disorders involving the skin, have collectively increased in incidence over the last 40 years. Sézary syndrome (SS) is an aggressive form of CTCL characterized by significant presence of malignant cells in both the blood and skin. The guarded prognosis for SS reflects a lack of reliably effective therapy, due in part to an incomplete understanding of disease pathogenesis. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3309DOI Listing
February 2019
18 Reads

Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study.

J Am Acad Dermatol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.

Background: Follicular mucinosis (FM), defined by mucin accumulation within follicular epithelium, may occur in mycosis fungoides (MF). FM without MF is occasionally reported in systemic hematologic malignancies, and may be diagnostically challenging.

Objective: To describe clinicopathological characteristics of FM in patients with hematologic malignancies other than MF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.01.062DOI Listing
February 2019
1 Read

Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.

Ann Hematol 2019 Feb 4. Epub 2019 Feb 4.

Jiangsu Institute of Haematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Epstein-Barr virus (EBV) reactivation is a life-threatening complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT). In this study, we investigated the characteristics of EBV reactivation in 186 consecutive myelodysplastic (MDS) patients who underwent allo-HSCT in our centre. In 35 patients (18. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-019-03603-3
Publisher Site
http://dx.doi.org/10.1007/s00277-019-03603-3DOI Listing
February 2019
2 Reads

What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Authors:
Marshall E Kadin

Aesthet Surg J 2019 Jan;39(Supplement_1):S28-S35

Professor of Dermatology, Boston University School of Medicine and Roger Williams Medical Center, Providence, RI.

Cytokines, their receptors, and downstream signaling partners, especially JAK1/2 and STAT3, are key biomarkers in lymphoproliferative disorders including systemic anaplastic large cell lymphoma (ALCL). Here we review their role in breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Early results suggest that, in addition to CD30, IL-9, IL-10, and IL-13 can distinguish malignant from benign seromas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy250DOI Listing
January 2019
1 Read

Endobronchial Manifestation of Methotrexate-induced Lymphoproliferative Disorder.

Intern Med 2019 Feb 1. Epub 2019 Feb 1.

Department of Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Japan.

Lymphoproliferative disorders can occur in patients with autoimmune disorders who undergo long-term methotrexate therapy (MTX-LPD). Although the manifestations of MTX-LPD are diverse, little attention is paid to endobronchial involvement. We herein describe two patients with MTX-LPD who presented with parenchymal pulmonary tumors and endobronchial involvement of LPD; one had lymphomatoid gramulomatosis and the other LPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2109-18DOI Listing
February 2019

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Lancet Haematol 2019 Feb;6(2):e100-e109

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.

Methods: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183021
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30216-3DOI Listing
February 2019
3 Reads

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

Front Pediatr 2018 17;6:405. Epub 2019 Jan 17.

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Epstein Barr virus positive T/NK lymphoproliferative disorders (EBV-TNKLPD) comprise a spectrum of neoplasms ranging from cutaneous lymphoid proliferations to aggressive lymphomas. The spectrum includes extranodal NK/T-cell lymphoma (ENKTL), aggressive NK-cell leukemia, and a group of EBV-TNKLPDs affecting children which are poorly characterized in terms of their molecular biology. Gene and miRNA expression profiling has elucidated RNA abnormalities which impact on disease biology, classification, and treatment of EBV-TNKLPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2018.00405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344448PMC
January 2019
1 Read

IgG4-related disease: what a hematologist needs to know.

Haematologica 2019 Jan 31. Epub 2019 Jan 31.

Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, Canada.

IgG4-related disease is a fibroinflammatory condition that can affect nearly any organ system. Common presentations include major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal fibrosis and tubulointerstitial nephritis. This review focuses on the hematological manifestations of IgG4-related disease, including lymphadenopathy, eosinophilia, and polyclonal hypergammaglobulinemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205526DOI Listing
January 2019
2 Reads

Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System.

Med Clin North Am 2019 Mar 3;103(2):325-336. Epub 2018 Dec 3.

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address:

Autoimmune disorders of the central nervous system are common and often affect people in the most productive years of their lives. Among primary autoimmune diseases of the central nervous system, multiple sclerosis is most prevalent in the United States. Many other autoantibody-mediated neurologic syndromes have been identified within the past 2 to 3 decades, including neuromyelitis optica and anti-N-methyl-D aspartate receptor encephalitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcna.2018.10.004DOI Listing
March 2019
1 Read

Cyclophosphamide for the treatment of acute lymphoblastic leukemia: A protocol for systematic review.

Medicine (Baltimore) 2019 Feb;98(5):e14293

Department of Hematology.

Background: Previous clinical trials have reported that cyclophosphamide can be used for the treatment of acute lymphoblastic leukemia (ALL). However, its efficacy is still unclear. In this systematic review study, we aim to evaluate its efficacy and safety for ALL. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201902010-0004
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000014293DOI Listing
February 2019
7 Reads

A Reactive Peripheral Gamma-Delta T-cell Lymphoid Proliferation After a Tick Bite.

Am J Dermatopathol 2019 Jan 22. Epub 2019 Jan 22.

Pathology, University of Virginia, Charlottesville, VA.

Peripheral gamma-delta T-cell proliferations are encountered in reaction to certain infections and in primary malignancies. Identifying sources of benign reactions is key in avoiding unnecessary workup and surveillance of these aggressive malignancies. Borrelia infections have been implicated in a number of lymphoproliferative disorders, but rarely, if ever, in this setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001352DOI Listing
January 2019
4 Reads

CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.

Authors:
Yijia Li

N Engl J Med 2019 01;380(5):497

University of Pittsburgh Medical Center, Pittsburgh, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816156DOI Listing
January 2019
1 Read

CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.

N Engl J Med 2019 01;380(5):496-7

University Medical Center, Utrecht, the Netherlands

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816156DOI Listing
January 2019
1 Read

HCV-associated mixed cryoglobulinemia and b-cell non-Hodgkin's lymphoma - pathogenetically related problems.

Ter Arkh 2018 Jun;90(6):112-120

I.M. Sechenov First Moscow State Medical Univesity, Ministry Health of Russia (Sechenov University), Moscow, Russia.

Hepatitis C virus (HCV) is a global population problem due to its high prevalence, usually late diagnosis, the difficulties of treatment. In the prognosis of patients with HCV not only hepatic, but increasingly frequent of extrahepatic HCV manifestations, such as mixed cryoglobulinemia (CG), are important. Mixed CG is currently considered as a B-cell benign lymphoproliferative disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh2018906112-120DOI Listing
June 2018
1 Read

Ewing's Sarcoma and Primary Osseous Lymphoma: Spectrum of Imaging Appearances.

Semin Musculoskelet Radiol 2019 Feb 30;23(1):36-57. Epub 2019 Jan 30.

Department of Radiology, AZ Sint-Maarten Mechelen, University Hospital Antwerp, Ghent University, Mechelen, Belgium.

Ewing's sarcoma (ES) is a rare, highly malignant anaplastic stem cell tumor. Histologically, the tumor consists of uniform densely packed small monomorphic cells with round nuclei. The typical appearance at hematoxylin and eosin (H&E) staining is small blue round cells without any matrix formation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1676125DOI Listing
February 2019
3 Reads

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.

N Engl J Med 2019 01;380(5):497-498

Forty Seven, Menlo Park, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1816156DOI Listing
January 2019
3 Reads

Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders.

Cancer Med 2019 Jan 29. Epub 2019 Jan 29.

Division of Pediatric Infectious Diseases, Washington University School of Medicine, St Louis, MO, USA.

Posttransplant lymphoproliferative disorders (PTLDs), 50%-80% of which are strongly associated with Epstein-Barr virus (EBV), carry a high morbidity and mortality. Most clinical/epidemiological/tumor characteristics do not consistently associate with worse patient survival, so our aim was to identify if other viral genomic characteristics associated better with survival. We extracted DNA from stored paraffin-embedded PTLD tissues at our center, identified viral sequences by metagenomic shotgun sequencing (MSS), and analyzed the data in relation to clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.1985
Publisher Site
http://dx.doi.org/10.1002/cam4.1985DOI Listing
January 2019
7 Reads

Primary immune regulatory disorders for the pediatric hematologist and oncologist: A case-based review.

Pediatr Blood Cancer 2019 Jan 29:e27619. Epub 2019 Jan 29.

Department of Hematology, Children's Hospital of Orange County, Orange, California.

An array of monogenic immune defects marked by autoimmunity, lymphoproliferation, and hyperinflammation rather than infections have been described. Primary immune regulatory disorders pose a challenge to pediatric hematologists and oncologists. This paper focuses on primary immune regulatory disorders including autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like syndromes, immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-like disorders, common variable immunodeficiency (CVID), CVID-like, and late-onset combined immunodeficiency (CID) disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27619DOI Listing
January 2019
1 Read

Cutaneous eruptions associated with hematologic malignancies: the need for a unifying nomenclature.

J Eur Acad Dermatol Venereol 2019 Jan 29. Epub 2019 Jan 29.

Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

we read with interest the study by Visseaux et al., entitled "T-cell papulosis associated with B-cell malignancies: a distinctive clinicopathologic entity". Herein, the authors reviewed retrospectively 37 patients with B-cell malignancies, mostly B-cells chronic lymphocytic leukaemia (B-CLL), showing recurrent episodes of pruritic papules, papulo-vesicles or nodules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15452DOI Listing
January 2019
1 Read

Lymphoma in Australian Border Collies: survey results and pedigree analyses.

Aust Vet J 2019 Jan;97(1-2):14-22

Sydney School of Veterinary Science and School of Life and Environmental Sciences, Faculty of Science, Evelyn Williams Building B10, The University of Sydney, New South Wales 2006, Australia.

Objectives: The aims of this study were to (1) describe the results of a survey on the clinical features of lymphoma in Australian Border Collies and (2) investigate familial clustering of lymphoma-affected dogs by means of pedigree analyses.

Methods: Clinical and pedigree information was collected from surveys completed by owners or breeders of Australian Border Collies. Relationships between dogs were derived from pedigree data and kinship was analysed by network and cluster-based algorithms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/avj.12780DOI Listing
January 2019

Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application.

Radiat Oncol 2019 Jan 28;14(1):17. Epub 2019 Jan 28.

School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.

Background: Helical irradiation of the total skin (HITS) was modified as simultaneous integrated boost (SIB)-helical arc radiotherapy of total skin (HEARTS) technique and applied to an acute myeloid leukemia (AML) patient with disseminated leukemia cutis.

Methods: The original HITS plan was revised for different regimens, i.e. Read More

View Article

Download full-text PDF

Source
https://ro-journal.biomedcentral.com/articles/10.1186/s13014
Publisher Site
http://dx.doi.org/10.1186/s13014-019-1220-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348688PMC
January 2019
4 Reads

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

Chin Clin Oncol 2019 Jan 9. Epub 2019 Jan 9.

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.12.03DOI Listing
January 2019
1 Read

Traitement par cellules CAR-T : état des lieux de leur utilisation aux États-Unis en 2018.

Authors:
Jordan Gauthier

Bull Cancer 2018 Dec;105 Suppl 2:S214-S217

Fred Hutchinson Cancer Research Center, Seattle, WA, États-Unis. Electronic address:

Car-t Therapy: CURRENT USE IN THE UNITED STATES IN 2018: Treatment with T-cells engineered with chimeric antigen receptors (CAR T-cell therapy) has been a field of intense research in the United States since the 1980s. The recent approval in August 2017 of Kymriah (tisagenlecleucel) opened the door to broader access to CAR T-cell therapy outside of clinical trials. Here, we aim to give the reader a practical summary of the current practices in the US when considering a patient for CAR T-cell therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193005
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30052-9DOI Listing
December 2018
3 Reads

L’émergence des traitements par cellules CAR-T dans les lymphomes.

Bull Cancer 2018 Dec;105 Suppl 2:S168-S177

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, 69495 Pierre Bénite cedex, France; Université Claude Bernard Lyon-1, 69100 Villeurbanne, France.

Emerging Therapies Using Car-t Cells In Lymphoma: After the promising results obtained in North American academic centers suggesting the curative potential of these treatments, the development of T cells carrying a chimeric antigen receptor (CAR-T) directed against the CD19 antigen has experienced rapid developments in recent years. Three major trials (each involving about 100 patients with relapsed or refractory aggressive B-cell lymphoma) were conducted and evaluated the efficacy of these treatments (Zuma-1, Juliet and Transcend). Tumor responses are observed in 52% to 82% of patients, with a best complete response (CR) rate of 40% to 58%. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30047-5DOI Listing
December 2018
3 Reads

Traitement par CAR-T des leucémies aiguës de l'adulte.

Bull Cancer 2018 Dec;105 Suppl 2:S158-S167

Unité d'Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, 75010 Paris, France; EA-3518, Unité de Recherche Clinique Appliquée à l'Hématologie, Institut Universitaire d'Hématologie, Université Paris Diderot, 75010 Paris, France. Electronic address:

Car-t Treatment Of Acute Leukemia In Adults: The prognosis for acute lymphoblastic leukemia (ALL) in adults remains poor in refractory or relapsed (R/R) situations. Among the immunotherapy strategies that have recently been developed, CAR-T cells (chimeric antigen receptor modified T-cells) represent a major technological and therapeutic advance in the management of adult and pediatric patients with such resistant diseases. The first CAR-T trials targeting the ubiquitous B-cell antigen CD19 showed very encouraging results with complete remission rates of approximately 80%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(19)30046-3DOI Listing
December 2018
4 Reads

CAR-T cells : indications actuelles en pédiatrie et perspectives de développement.

Bull Cancer 2018 Dec;105 Suppl 2:S147-S157

Service d'Hématologie Pédiatrique, Hôpital Universitaire Robert Debré (APHP), 75019 Paris, France; Université Paris Diderot, 75010 Paris, France; EA 3518 Institut Universitaire d'Hématologie, 75010 Paris, France. Electronic address:

Car T Cells: CURRENT INDICATIONS IN CHILDREN AND PERSPECTIVES: Acute lymphoblastic leukemia (ALL) is the first cause of cancer in children. Five-year overall survival is greater than 90% but leukemia remains a major cause of death from cancer in children. A new class of immunotherapy based on a chimeric antigen receptor "CAR" targeting the CD19 on the B leukemic cells and that is transduced in an autologous or allogenic T lymphocyte will allow to transform the prognosis of refractory or relapsed B-ALL. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30045-1DOI Listing
December 2018
2 Reads

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

Leukemia 2019 Jan 25. Epub 2019 Jan 25.

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0380-5DOI Listing
January 2019
2 Reads